A citation-based method for searching scientific literature

Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee, Sven Kohler, Yutaka Seino. J Diabetes Investig 2019
Times Cited: 9







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®.
Kohei Kaku, Jisoo Lee, Michaela Mattheus, Stefan Kaspers, Jyothis George, Hans-Juergen Woerle. Circ J 2017
65
55

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
44

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
44

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
44

Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Kazuki Koiwai, Henning Rattunde, Hans J Woerle, Uli C Broedl. Adv Ther 2015
33
33

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
335
33


No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han, Linong Ji. J Diabetes Investig 2018
26
33


Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
173
22


Japanese Clinical Practice Guideline for Diabetes 2016.
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki. J Diabetes Investig 2018
116
22


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
22

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
926
22

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin, Mehdi Najafzadeh, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Steven Sambevski, Lily G Bessette, Adrian J Santiago Ortiz, Martin Kulldorff,[...]. Circulation 2019
72
22

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Tim Heise, Jens Jordan, Christoph Wanner, Martina Heer, Sreeraj Macha, Michaela Mattheus, Søren S Lund, Hans J Woerle, Uli C Broedl. Clin Ther 2016
45
22

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.
Atsutaka Yasui, Ganghyuck Lee, Tetsuaki Hirase, Tatsuroh Kaneko, Stefan Kaspers, Maximilian von Eynatten, Tomoo Okamura. Diabetes Ther 2018
22
22

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Hristo Iliev, Egon Pfarr, Bernard Zinman. Diabetes Care 2018
85
22

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel,[...]. Diabetes Ther 2018
54
22

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang, Wei Wang, Yuting Mu, Ping Yan, Sharon Pan, Brett Lauring,[...]. Diabetes Obes Metab 2019
19
22


Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
80
22

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
L Ji, P Han, Y Liu, G Yang, N K Dieu Van, U Vijapurkar, R Qiu, G Meininger. Diabetes Obes Metab 2015
49
22


Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
David R Matthews, Qiang Li, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, William R Hiatt, Mark Nehler, Elisa Fabbrini,[...]. Diabetologia 2019
45
22

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, Fernando Solimando, Christopher Lee, Jisoo Lee, Jyothis George. Diabetes Obes Metab 2018
19
22

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
22

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
Karin Rådholm, Jason Hy Wu, Muh Geot Wong, Celine Foote, Gregory Fulcher, Kenneth W Mahaffey, Vlado Perkovic, Bruce Neal. Diabetes Res Clin Pract 2018
41
22

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
249
22

An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
47
22

Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.
Merlin C Thomas, Mark E Cooper, Paul Zimmet. Nat Rev Nephrol 2016
193
22


Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
423
11

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
Michael A Nauck, Juris J Meier. Lancet Diabetes Endocrinol 2016
10
11

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
E Araki, Y Tanizawa, Y Tanaka, A Taniguchi, K Koiwai, G Kim, A Salsali, H J Woerle, U C Broedl. Diabetes Obes Metab 2015
38
11

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
11



Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.
Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa, Arihiro Kiyosue, Yumiko Ide, Takuto Tokudome, Yuji Hoshino, Jisin Yang, Anna Maria Langkilde. Diabetes Ther 2014
49
11

SGLT2 inhibition--a novel strategy for diabetes treatment.
Edward C Chao, Robert R Henry. Nat Rev Drug Discov 2010
387
11


Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
Kazunori Utsunomiya, Naoki Shimmoto, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Seigo Kakiuchi, Hisataka Fujiwara, Hiroyuki Kameda, Masahiro Tamura,[...]. J Diabetes Investig 2017
24
11




Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.
Xiaoling Cai, Liwei Ji, Yifei Chen, Wenjia Yang, Lingli Zhou, Xueyao Han, Simin Zhang, Linong Ji. J Diabetes Investig 2017
23
11

Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Tomohiko Kimura, Junpei Sanada, Masashi Shimoda, Hidenori Hirukawa, Yoshiro Fushimi, Momoyo Nishioka, Tomoe Kinoshita, Seizo Okauchi, Atsushi Obata, Kenji Kohara,[...]. J Diabetes Investig 2018
8
12

β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians.
Daisuke Yabe, Yutaka Seino, Mitsuo Fukushima, Susumu Seino. Curr Diab Rep 2015
137
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.